Eli Lilly Claims New Drug Can Slow Alzheimer’s-Related Decline

Patients who received the drug fared better cognitively and functionally than those taking placebo, but still experienced losses in performance.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: © ISTOCK.COM, SELVANEGRA

The US Food and Drug Administration has not approved a new drug to treat Alzheimer’s disease since 2003. In an effort to end that drought, Eli Lilly, an Indianapolis-based pharmaceutical company, has developed a drug called donanemab, an antibody designed to clear deposits of amyloid-β peptides that form plaques in the brains of patients with AD. At the International Conference on Alzheimer’s and Parkinson's Diseases, held virtually March 9–14, researchers from Lilly announced Phase 2 trial results that donanemab slowed the progression of the disease. The study was published Saturday (March 13) in the New England Journal of Medicine during the team’s presentation.

The study followed 257 patients with early stages of AD over the course of 76 weeks. The primary endpoint of the study was measured by scores on the integrated Alzheimer’s Disease Rating Scale (iADRS). The score is based on two common systems used ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Lisa Winter

    Lisa Winter became social media editor for The Scientist in 2017. In addition to her duties on social media platforms, she also pens obituaries for the website. She graduated from Arizona State University, where she studied genetics, cell, and developmental biology.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide